Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

15.39USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$15.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
174,909
52-wk High
$34.98
52-wk Low
$15.14

Latest Key Developments (Source: Significant Developments)

Cytomx Therapeutics Inc - QTRLY Net Loss Per Share $0.35
Wednesday, 8 Aug 2018 

CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $21.3 MILLION VERSUS I/B/E/S VIEW $19.2 MILLION.QTRLY NET LOSS PER SHARE $0.35.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.  Full Article

Cytomx Therapeutics Says Public Offering Of 5.10 Mln Common Shares Priced At $24.50/ Share
Friday, 13 Jul 2018 

July 12 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.10 MILLION COMMON SHARES PRICED AT $24.50PER SHARE.  Full Article

CytomX Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 10 Jul 2018 

July 10 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CYTOMX THERAPEUTICS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION OF SHARES OF ITS COMMON STOCK.CYTOMX THERAPEUTICS - EXPECTS TO GRANT UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL $18.75 MILLION OF SHARES OF STOCK AT PUBLIC OFFERING PRICE.CYTOMX THERAPEUTICS - EXPECTS TO USE PROCEEDS FROM OFFERING TO DEVELOP ITS PROPRIETARY PROBODY THERAPEUTIC PIPELINE & TO ADVANCE ADDITIONAL PROGRAMS.  Full Article

Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8
Monday, 18 Dec 2017 

Dec 18 (Reuters) - CytomX Therapeutics Inc ::PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING.  Full Article

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

CytomX reports Q3 loss per share $‍0.28​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - CytomX Therapeutics Inc :CytomX announces third quarter 2017 financial results and operational progress.Q3 revenue $24.1 million versus $3.5 million.Q3 revenue view $17.5 million -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc qtrly loss per share $‍0.28​.  Full Article

CytomX says clinical candidate probody from Bristol-Myers Squibb collaboration selected
Tuesday, 13 Dec 2016 

CytomX Therapeutics Inc : CytomX announces selection by Bristol-Myers Squibb of first clinical candidate probody from collaboration . Upon selection of third and fourth targets, Bristol-Myers Squibb paid CytomX selection payments .Achieving this milestone results in a $2 million payment to CytomX.  Full Article